0.15Open0.15Pre Close8 Volume527 Open Interest4.00Strike Price145.00Turnover52.97%IV3.80%PremiumDec 20, 2024Expiry Date0.05Intrinsic Value100Multiplier16DDays to Expiry0.15Extrinsic Value100Contract SizeAmericanOptions Type-0.5164Delta0.9023Gamma19.75Leverage Ratio-0.0052Theta-0.0009Rho-10.20Eff Leverage0.0033Vega
Geron Stock Discussion
Almost low enough
Geron Corp - Receives $250 Million at Closing, $125 Million in Debt Available
Royalty Pharma to Acquire Royalty Interest in Geron’s Rytelo for $125 Million
Achieved $28.2 million in RYTELO(TM) (imetelstat) net product revenue in first full quarter of sales
Received $250 million in gross proceeds from synthetic royalty and debt financings with Royalty Pharma and Pharmakon Advisors, with access to an additional $125 million in debt
No comment yet